DK2041308T3 - Fremgangsmåde til detektion og diagnosticering af cancer, som involverer primere og prober til den specifikke detektion af MAGE-A3-markøren - Google Patents

Fremgangsmåde til detektion og diagnosticering af cancer, som involverer primere og prober til den specifikke detektion af MAGE-A3-markøren

Info

Publication number
DK2041308T3
DK2041308T3 DK07786793.5T DK07786793T DK2041308T3 DK 2041308 T3 DK2041308 T3 DK 2041308T3 DK 07786793 T DK07786793 T DK 07786793T DK 2041308 T3 DK2041308 T3 DK 2041308T3
Authority
DK
Denmark
Prior art keywords
detection
mage
probes
marker
diagnosis
Prior art date
Application number
DK07786793.5T
Other languages
Danish (da)
English (en)
Inventor
Thierry Coche
Olivier Gruselle
Gabriele Anne-Marie Beer
Dennis Salonga
Craig Lawrence Stephens
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Application granted granted Critical
Publication of DK2041308T3 publication Critical patent/DK2041308T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091Purification or manufacturing processes for gene therapy compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6841In situ hybridisation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/16Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Manufacturing & Machinery (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK07786793.5T 2006-06-21 2007-06-21 Fremgangsmåde til detektion og diagnosticering af cancer, som involverer primere og prober til den specifikke detektion af MAGE-A3-markøren DK2041308T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0612342.6A GB0612342D0 (en) 2006-06-21 2006-06-21 Method
PCT/EP2007/056219 WO2007147876A2 (en) 2006-06-21 2007-06-21 Method for the detection and diagnosis of cancer involving primers and probes for the specific detection of the mage- a3 -marker

Publications (1)

Publication Number Publication Date
DK2041308T3 true DK2041308T3 (da) 2012-10-08

Family

ID=36803668

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07786793.5T DK2041308T3 (da) 2006-06-21 2007-06-21 Fremgangsmåde til detektion og diagnosticering af cancer, som involverer primere og prober til den specifikke detektion af MAGE-A3-markøren

Country Status (27)

Country Link
US (1) US8936919B2 (https=)
EP (1) EP2041308B1 (https=)
JP (2) JP2009540812A (https=)
KR (1) KR101455589B1 (https=)
CN (1) CN101506383B (https=)
AU (1) AU2007263019B2 (https=)
BR (1) BRPI0713599A2 (https=)
CA (1) CA2656909A1 (https=)
CO (1) CO6140072A2 (https=)
CY (1) CY1113290T1 (https=)
DK (1) DK2041308T3 (https=)
EA (1) EA016347B1 (https=)
ES (1) ES2389513T3 (https=)
GB (1) GB0612342D0 (https=)
HR (1) HRP20120761T1 (https=)
IL (1) IL195975A (https=)
MA (1) MA30565B1 (https=)
MX (1) MX2008016493A (https=)
MY (1) MY147511A (https=)
NO (1) NO20085290L (https=)
NZ (1) NZ573809A (https=)
PL (1) PL2041308T3 (https=)
PT (1) PT2041308E (https=)
SI (1) SI2041308T1 (https=)
UA (1) UA95956C2 (https=)
WO (1) WO2007147876A2 (https=)
ZA (1) ZA200810695B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008300397A1 (en) 2007-09-17 2009-03-26 Glaxosmithkline Biologicals S.A. Improved detection of MAGE-A expression
JP5883443B2 (ja) * 2010-07-22 2016-03-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規の抗原結合タンパク質
CN102251033B (zh) * 2011-07-05 2013-03-20 北京大学人民医院 基于mage-a3基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612201A (en) * 1991-05-23 1997-03-18 Ludwig Institute For Cancer Research Isolated nucleic acid molecules useful in determining expression of a tumor rejection antigen precursor
WO1994003205A1 (en) * 1992-08-07 1994-02-17 Cytel Corporation Hla binding peptides and their uses
CA2184482A1 (en) * 1994-03-01 1995-09-08 Etienne De Plaen Determination of cancerous conditions by mage gene expression
US5985571A (en) * 1998-02-04 1999-11-16 Ludwig Institute For Cancer Research Method for determining multiple myeloma by assaying for expression of mage genes
CZ298364B6 (cs) * 1998-02-05 2007-09-05 Smithkline Beecham Biologicals S. A. Deriváty antigenu asociovaných s nádory z MAGE rodiny a sekvence nukleových kyselin kodující tyto deriváty, jejich použití pro prípravu fúzních proteinu a prostredku pro vakcinaci
WO2000020445A2 (en) * 1998-10-02 2000-04-13 Ludwig Institute For Cancer Research Tumor antigens and ctl clones isolated by a novel procedure
JP3603138B2 (ja) * 2000-02-18 2004-12-22 独立行政法人理化学研究所 細胞死抑制タンパク質
US6358679B1 (en) * 2000-08-24 2002-03-19 Pe Corporation (Ny) Methods for external controls for nucleic acid amplification
US6635425B2 (en) * 2001-01-05 2003-10-21 Molecular Staging, Inc. 5′-thio phosphate directed ligation of oligonucleotides and use in detection of single nucleotide polymorphisms
US7771998B2 (en) * 2001-11-29 2010-08-10 Dandrit Biotech A/S Pharmaceutical composition for inducing an immune response in a human or animal
AU2003295600A1 (en) 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
EP1572105B1 (en) * 2002-11-14 2011-08-31 John Wayne Cancer Institute Detection of micro metastasis of melanoma and breast cancer in paraffin-embedded tumor draining lymph nodes by multimaker quantitative rt-pcr
GB0409940D0 (en) * 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
US20070231822A1 (en) * 2006-02-28 2007-10-04 Michael Mitas Methods for the detection and treatment of cancer

Also Published As

Publication number Publication date
CO6140072A2 (es) 2010-03-19
SI2041308T1 (sl) 2012-10-30
CN101506383B (zh) 2013-08-28
KR101455589B1 (ko) 2014-10-28
PT2041308E (pt) 2012-10-09
HK1127627A1 (en) 2009-10-02
US20120040341A1 (en) 2012-02-16
US8936919B2 (en) 2015-01-20
JP5705191B2 (ja) 2015-04-22
AU2007263019B2 (en) 2012-11-08
WO2007147876A3 (en) 2008-05-15
JP2009540812A (ja) 2009-11-26
IL195975A0 (en) 2009-09-01
MX2008016493A (es) 2009-05-21
WO2007147876A2 (en) 2007-12-27
NZ573809A (en) 2011-12-22
JP2013046630A (ja) 2013-03-07
EP2041308B1 (en) 2012-07-11
IL195975A (en) 2012-08-30
ES2389513T3 (es) 2012-10-26
PL2041308T3 (pl) 2012-11-30
EP2041308A2 (en) 2009-04-01
UA95956C2 (uk) 2011-09-26
CN101506383A (zh) 2009-08-12
NO20085290L (no) 2009-01-19
MA30565B1 (fr) 2009-07-01
ZA200810695B (en) 2014-03-26
EA016347B1 (ru) 2012-04-30
CA2656909A1 (en) 2007-12-27
AU2007263019A1 (en) 2007-12-27
BRPI0713599A2 (pt) 2012-11-06
EA200802356A1 (ru) 2009-06-30
CY1113290T1 (el) 2016-04-13
GB0612342D0 (en) 2006-08-02
MY147511A (en) 2012-12-31
HRP20120761T1 (hr) 2012-10-31
KR20090034900A (ko) 2009-04-08

Similar Documents

Publication Publication Date Title
DK3567363T3 (da) Prøvningsindretninger, -fremgangsmåder og reagenser
DK2371958T3 (da) HIDTIL UKENDTE siRNA OG FREMGANGSMÅDER TIL ANVENDELSE DERAF
DK3461503T3 (da) Fremgangsmåder til indgivelse af tetrahydrobiopterin, associerede sammensætninger og målingsfremgangsmåder
BRPI0818801A2 (pt) Sistema de testes de diagnóstico.
BRPI0814320A2 (pt) Método para determinar automaticamente o estado de uso de um dispositivo médico eletrônico e/ou ativar dito dispositivo médico eletrônico, e, estetoscópio eletrônico.
WO2008039769A3 (en) Methods and devices for analyzing small rna molecules
EP2068698A4 (en) INCLUDED TEST UNIT FOR CHECKING BODY FLUIDS
DK2155188T3 (da) Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft
BRPI0819819A2 (pt) Preparações, método e kits ùteis para o tratamento de tosse
BRPI1010798A2 (pt) fechamento, aparelho de retenção, e método de uso do mesmo
DK2209375T3 (da) Parp-inhibitorforbindelser, præparater og fremgangsmåder til anvendelse deraf
EP1896842A4 (en) Non-destructive testing of pipes
BRPI0907605A2 (pt) Aparelho, montagem e método de teste submarino
EP2150625A4 (en) METHODS, COMPOSITIONS AND KITS FOR DETECTION AND ANALYSIS OF ANTIBIOTIC RESISTANT BACTERIA
BRPI1008534A2 (pt) aparelho e métodos para testar fluido de furo de poço
BRPI0814330A2 (pt) métodos e kits cirúrgicos
DK2021794T3 (da) Anvendelse af protein S100A 12 som en markør for colorektal cancer
BRPI0910030A2 (pt) método de teste ultra-sônico e equipamento para o mesmo.
BRPI0718850A2 (pt) Métodos de tratar, diagnosticar ou detectar câncer
EP2281903A4 (en) CANCER MARKER, METHOD FOR EVALUATING CANCER USING THE CANCER MARKER AND ASSESSING THE VALUE
NO20083908L (no) Fluidanalysesystem og metode for drift av et analysesystem
ZA200808669B (en) Methods of treating, diagnosing or detecting cancer
DK1976884T3 (da) Anti-ephrinb2-antistoffer og fremgangsmåder til anvendelse deraf.
EP2326253A4 (en) INTEGRATED SURGICAL SPECIMEN SENSOR
EP2011871A4 (en) PRIMER AND PROBE FOR THE DETECTION OF MYCOBACTERIUM INTRACELLULARE AND METHOD FOR THE DETECTION OF MYCOBACTERIUM INTRACELLULARE USING THE PRIMER AND THE PROBE